Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568586 | 0.92 | TLR9 (0.44) | TLR9TLR7CHRM4DRD2HTR7 | |
| SCHEMBL4568428 | 0.91 | TLR9 (0.41) | TLR9TLR7TLR8MTNR1AMTNR1B | |
| SCHEMBL4568192 | 0.89 | KDM4E (0.42) | CHRM4DRD2HTR7JAK2MTNR1A | |
| SCHEMBL4568498 | 0.87 | TLR9 (0.43) | TLR9TLR7TLR8MTNR1AMTNR1B | |
| SCHEMBL4568473 | 0.87 | TLR9 (0.41) | TLR9TLR7TLR8MAPTPARP1 | |
| SCHEMBL4568427 | 0.86 | TUBB4A (0.46) | — | |
| SCHEMBL4568483 | 0.86 | TLR9 (0.42) | TLR9TLR7TLR8MAPTKMT2A | |
| SCHEMBL3706006 | 0.84 | MTNR1A (0.48) | HTR7MTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL4568175 | 0.83 | PTGS2 (0.42) | MTNR1AMTNR1BMAPTMEN1KMT2A | |
| SCHEMBL4568432 | 0.82 | PLA2G2A (0.40) | JAK2MTNR1AMTNR1BMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | TLR9 1840/4885TLR7 1083/4885TLR8 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.